Optain, formerly known as Eyetelligence Pty Ltd, is a company that has integrated with its parent company, Optain Health. The company aims to deliver value to customers, partners, and stakeholders in the healthcare sector.

Optain

See with certainty
Optain is an international MedTech company, developing advanced AI software solutions.

Eyetelligence Assure software analyses full-colour fundus images to screen for referable eye diseases including glaucoma, diabetic retinopathy, and
age-related macular degeneration. Additionally, the technology can screen for cardiovascular diseases and provide a risk assessment profile.

Our vision is to harness the power of AI to provide affordable clinical support tools that make disease screening easy, anytime, anywhere.

Optain (Australia)

We are here at the National Aboriginal and Torres Strait Islander Eye Health Conference (NATSIEHC24) in Hobart! 
Optain is showcasing our cutting-edge retinal imaging technology and AI-powered software. Our state-of-the-art products, Assure Plus software suite and our portable fundus camera are revolutionizing eye care by providing quick and accurate detection of eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Additionally, our technology can screen for cardiovascular disease risks, offering a comprehensive view of your health. 
We are deeply committed to improving eye health in Aboriginal and Torres Strait Islander communities. Our innovative solutions are designed to make disease screening accessible and affordable, ensuring that everyone, regardless of location, has access to high-quality eye care. 

See with certainty

#NATSIEHC24 #EyeHealth #AIinHealthcare #DiabeticRetinopathy #Glaucoma #AMD #CVD #DigitalHealthcare #Hobart #AboriginalEyeHealth

Many thanks to all the amazing people we met at this year's APAO Congress in Bali, Indonesia. The response we received at the show was overwhelmingly positive and we see big things on the horizon for us in APAC region.

Special thanks to Sanil Joseph for his outstanding presentation on the future of AI in healthcare and ophthalmology. 

At Optain we are harnessing the power of AI to see into the future of health, where the early detection of chronic disease through AI-empowered health assessments is universally accessible to all. 

#APAO #artificialintelligence #Screening #opthalmology

At this years @APAO be sure not to miss Sanil Joseph give a special in-booth presentation at 13:15 on Friday the 23rd Feb.
Presenting his views on the exciting future of AI in healthcare and Ophthalmology.

#APAO Optain (Australia) #AI #screening #futurist

Babak Asgari from Optain (Australia) welcoming and inviting you to visit at APAO in Bali.
#APAO #Optain #Eyetelligence #AI #screening

We're proud to be attending this years APAO in Bali Feb 22-25.
Make sure to see us at Booth 104/123
To experience the latest in AI screening tools.
#APAO #opthalmology #AI #Screening #glaucoma #Optain #Eyetelligence

We are honored to be recognized in the 2024 New York Digital Health 100. This is a testament to the dedication of our New York, Melbourne, and globally-based team, and reinforces our commitment to democratizing access to care via our revolutionary oculomics and AI platform.

Optain has been named to the Digital Health Top 100!

Now in its 5th year, #DH100 celebrates the most innovative and exciting healthcare startups in the NY region. We’re grateful to be included among other leading companies dedicated to reimagining healthcare. See the full list and more in the 2024 New York Healthcare Innovation Report https://lnkd.in/gz8zCmSZ 
 
We’re proud to be on the list and in such good company! Excited to announce that Optain has been featured on this year’s Digital Health 100. This list, published by @Digital Health New York, celebrates the most innovative and exciting startups in the NY healthcare ecosystem. See the full #DH100 list and read more about the trends impacting the industry in the 2024 New York Healthcare Innovation Report https://lnkd.in/gz8zCmSZ 
 
Honored to be included on this year’s Digital Health 100 – the annual list published by @Digital Health New York that celebrates the most innovative and promising healthcare startups in the NY region. See the full #DH100 list and more in the 2024 New York Healthcare Innovation Report https://lnkd.in/gz8zCmSZ

Visit Optain at Arab Health for us to show you how we open a window through the eyes to see the future of healthcare.

The ACT / Optain booth is located at Arab Health Exhibition, US Pavilion, H1 G19, Maryland Department of Trade booth in the US Pavillion. 29 Jan - 1 Feb 2024.
Optain will also be showcased in the Canadian Business Council booth located Canadian Business Council of Dubai and the Northern Emirates booth, H6 F10



#arabhealth2024 #arabhealth #artificialintelligence #ai #digitalhealthcare #optical #ophthalmology #optometry #primaryhealthcare #diseasedetection #optain

Eyetelligence changes name to Optain
 
Eyetelligence Pty Ltd, is excited to announce a significant milestone in its growth and evolution. Effective October 1st, the company officially changed its name to Optain. This strategic decision reflects the alignment and integration of Eyetelligence with its parent company, Optain Health, following substantial investments that have reinforced our commitment to excellence and innovation. The change of name to Optain signifies a new chapter in our journey, as we harness the synergy and resources of Optain Health to deliver even greater value to our customers, partners, and stakeholders. Optain will continue to provide the same high-quality AI powered solution and unwavering dedication to customer satisfaction that you have come to expect. Our core values and mission remain unchanged, and this transition only strengthens our ability to deliver on our promises.
 
"We are excited about this change, which represents a strategic alignment with our parent company's vision and values," said Rainer Grote, Senior Vice President at Optain. "We believe this move will open up new opportunities for innovation and growth, allowing us to better serve our customers and drive industry-leading solutions."
 
The transition to Optain will not impact our existing contracts, agreements, or ongoing business relationships. Our website, email addresses, and all communication channels will be updated to reflect the new name, ensuring a smooth transition for all stakeholders. We want to thank our loyal customers, partners, and employees for their continued support and commitment. We are excited about the future and look forward to sharing this exciting journey with you.

Metric
Company Name	Optain
Symbol
MSH ID	AI:EYETELLIGENCE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Digital Health
Country	AU
Stage
Employee Count
Website	eyetelligence.ai
LinkedIn	optainhealthau
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

EYET

AI:EYETELLIGENCE

Optain

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue